About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Patients Derived Organoids in Ovarian Cancer | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT06085404

Patients Derived Organoids in Ovarian Cancer

Among cancer models, patients derived organoids (PDOs) best reproduce tumor's tissue architecture, intratumor heterogeneity and are able to mimic in vivo patients' drugs response. For these reasons, ...

Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Camilla Nero, PhD

CONTACT

+390630158667 camilla.nero@policlinicogemelli.it

Sponsors

Lead Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Age

18 - 80 years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•1. Preoperative clinical, serological and radiologic suspicion of International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or greater ovarian, fallopian tube, or primary peritoneal cancer;
•2. Histologic diagnoses of epithelial ovarian cancer at frozen section
•3. Age \>18 and years;
•4. Estimated life expectancy of at least 4 weeks;
•5. Performance status (PS) according to Eastern Cooperative Oncology Group (ECOG) \< 2

Exclusion Criteria

•1. Non-serous histology at frozen section;
•2. Patients with a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (\> 10 mg equivalent prednisone/daily) or any other form of immunosuppressive therapy within 7 days prior to the enrollment.

Related studies

Familial Investigations of Childhood Cancer Predisposition

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

RECRUITINGPhase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more

RECRUITINGPhase 1

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

NCT06964009 · Ovarian Cancer, Ovarian Carcinoma, and more

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

NCT00539162 · Ovarian Cancer

RECRUITINGPhase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403 · Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 4, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment48

Start dateNov 2021

Last updatedMar 4, 2025

Condition

Locations shown

Policlinico Universitario Agostino Gemelli

Roma

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions